A COMPARISON OF ORAL ONDANSETRON SYRUP OR INTRAVENOUS ONDANSETRON LOADING DOSE REGIMENS GIVEN IN COMBINATION WITH DEXAMETHASONE FOR THE PREVENTION OF NAUSEA AND EMESIS IN PEDIATRIC AND ADOLESCENT PATIENTS RECEIVING MODERATELY/HIGHLY EMETOGENIC CHEMOTHERAPY |
| |
| Authors: | L. White S. A. Daly C. J. McKenna N. Zhestkova C. Leal F. Breatnach |
| |
| Affiliation: | 1. Sydney Children's Hospital, Randwick, Sydney, Australia;2. Glaxo Wellcome Research &3. Development, Middlesex, UK;4. Russian Children's Republic Hospital, Moscow, Russia;5. National Institute of Pediatrics, Cuicuilco, Mexico;6. Our Lady's Hospital for Sick Children, Crumlin, Dublin, Ireland |
| |
| Abstract: | This double-blind, parallel-group, multicenter study compared the efficacy and safety of intravenous (IV) ondansetron with oral syrup ondansetron plus oral dexamethasone in the prevention of nausea and emesis in pediatric patients receiving moderately/highly emetogenic chemotherapy. On each day of chemotherapy, patients were administered on dansetron 5 mg/m2 IV and placebo syrup orally ( n = 215) orondansetron 8 mg syrup orally and placebo IV ( n = 223) plus dexamethasone 2-4 mg PO. Ondansetron 4 mg syrup PO was administered twice daily for 2 days following the cessation of chemotherapy. Complete or major control of emesis was obtained in 89% patients in the IV group and 88% patients in the oral syrup group during the worst day of chemotherapy treatment (90% CI: 6, 4) and in 85% and 82% patients, respectively, during the worst day of the study period (90% CI: 8, 3). Intravenous ororal syrup ondansetron plus dexamethasone was well tolerated and effective in preventing chemotherapy-induced emesis in pediatric patients. |
| |
| Keywords: | Chemotherapy Nausea Ondansetron Oral Syrup Vomiting |
|
|
